These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15077921)

  • 1. Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing.
    Luftner D; Henschke P; Kafka A; Anagnostopoulos I; Wiechen K; Geppert R; Stein H; Wernecke KD; Kreienberg R; Possinger K
    Int J Biol Markers; 2004; 19(1):1-13. PubMed ID: 15077921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
    Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
    Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
    Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
    Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
    Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
    J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
    Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
    Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
    Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
    Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay.
    Goud KI; Dayakar S; Vijayalaxmi K; Babu SJ; Reddy PV
    Indian J Med Res; 2012 Mar; 135(3):312-7. PubMed ID: 22561616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
    Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
    Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.
    Mostafa NA; Eissa SS; Belal DM; Shoman SH
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):41-6. PubMed ID: 22099935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.
    Kokate P; Sawaimoon S; Bhatia S; Mandava S
    Genet Test Mol Biomarkers; 2012 Apr; 16(4):239-45. PubMed ID: 22023243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
    Shukla S; Singh BK; Pathania OP; Jain M
    Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.